Background: Alternative polyadenylation (APA) shortens or lengthens the 3ʹ-untranslated region (3ʹ-UTR) of hundreds of genes in cancer. While APA genes modify microRNA target sites in the 3ʹ-UTRs to promote tumorigenesis, previous studies have focused on a subset of the modification landscape.
However, it is challenging to estimate the amount of APA-derived target site modification for miRNAs. First, while 3ʹUS removes miRNA target sites in the 3ʹ-UTRs, 3ʹUL plays a confounding role by adding the target sites back. Second, APA events and their associated miRNAs are on many-to-many relationships, making it difficult to pinpoint miRNAs that are collectively affected the most. To address these challenges, we developed a mathematical model that estimates the modification effect of global APA genes for each miRNA, Probabilistic Inference of MicroRNA Target Site Modification through APA (PRIMATA-APA).
We applied PRIMATA-APA on the TCGA breast cancer data [13] and found that APA modifies target sites of miRNAs known to regulate cancer etiology and treatments. Our prediction was further validated in the data from a previous study knocking down (KD) NUDT21, a master regulator of 3ʹ-UTR shortening, in HeLa cell. Since the NUDT21 KD induced broad 3'UTRshortening, leading to enhanced cellular proliferation in HeLa cells and glioblastoma tumor growth in vitro and in vivo, our validation confirms that APA events promote tumorigenesis by modifying target sites of miRNAs regulating tumorigenic process. Further analyses show that APA events affect tumor interpatient heterogeneity not dependent on miRNA expression changes but by modifying miRNA target sites.
Methods

TCGA breast tumor RNA-seq and miRNA-Seq data
Quantified gene expression files (RNASeqV1) for primary breast tumors and their matching solid normal samples were downloaded from TCGA Data Portal [51] . We used 106 breast tumor samples that have matched normal tissues. 10,868 expressed RefSeq genes (FPKM ≥ 1 in > 80% of all samples) were selected for downstream analyses. To better quantify gene expression in the 5 presence of 3ʹ-UTR shortening, we only used coding regions (CDS). Exon and CDS annotation for TCGA data and miRNA expressions (syn1445790) were downloaded from Sage Bionetworks' Synapse database.
Selection of miRNAs and genes
Predicted miRNA target sites were obtained from TargetScanHuman version 6.2 [52] . Only those with a preferentially conserved targeting score (Pct) more than 0 were used [6] . Experimentally validated miRNA-target sites were obtained from TarBase version 5.0 [53] , miRecords version 4 [54] and miRTarBase version 4.5 [55] . The target sites found in indirect studies such as microarray experiments and high-throughput proteomics measurements were filtered out [56] .
Another source is the microRNA target atlas composed of public AGO-CLIP data [57] with significant target sites (q-value < 0.05). The predicted and validated target site information was then combined to use in this study.
Probabilistic Inference of MicroRNA Target Site Modification through APA (PRIMATA-
APA)
For transcript with a constitutive proximal 3ʹ-UTR (pUTR) and a distal 3ʹ-UTR (dUTR), we previously defined the amount of target sites for miRNA miRj in all copies of transcript x as follows [8] . 
Results
Collective impact of APA genes for the trans effect
To identify APA events in large-scale data, several computational tools have been developed that use RNA-Seq data [6] , [14] - [17] . For example, statistically significant APA genes can be defined using the difference in Percentage of Distal polyA site Usage Index (∆PDUI) [6] . Among the significant APA genes from such tools, current analyses have focused mostly on a subset of them that strongly changed 3ʹ-UTR usage in tumor (strong APA genes). For example, studies on TCGA human cancer [6] and cell line data [7] focused on the strong APA genes (∆PDUI < -0.2 for 3ʹUS and ∆PDUI > 0.2 for 3ʹUL) selected from significant APA genes (FDR < 0.05).
However, strong APA genes account for only a small portion of all significant APA genes. For example, in TCGA tumor-normal sample pair BH-A1FJ with the greatest number of significant APA genes, the strong APA genes account only for 50.5% (1,523) of 3,015 significant APA genes ( Fig. 1A) . Across 106 breast tumor-matched normal sample pairs in TCGA, this trend is more pronounced in that only 40.5% of significant APA genes are strong APA genes on average ( Fig. 1B) .
We found that significant APA genes, strong or not, together elucidate the common trans mechanism of APA. In 106 normal/tumor sample pairs, we identified totally 6,825 significant 3ʹUS genes, of which 82.4% (5, 626) 1C ). In the previous studies studying cis effect of APA events, focusing on strong APA genes would be reasonable, since strong 3ʹUS genes are likely strong cis targets of 3ʹUS.
However, as 3ʹUS events exert the trans mechanism through modifying miRNA target sites [8] , significant-but-not-strong 3ʹUS genes contribute to the trans mechanism by modifying miRNA target sites on their 3ʹUTRs [18] , especially if they are highly expressed.
In the same sense, 3ʹUL genes need to be considered, since they would increase miRNA target sites to compensate for those decreased by 3ʹUS genes. Previous studies reported smaller numbers of 3ʹUL genes than 3ʹUS from TCGA cancer patients [6] or cancer cell lines [7] . This was partly because they focused only on strong APA genes common to the samples. Considering all significant APA genes in our TCGA breast cancer analysis, we found that 3ʹUL is as widespread as 3ʹUS. For example, in TCGA tumor-normal sample pair AC-A2FB, which has the smallest ratio of strong APA genes to significant APA genes, 90.1% of the significant APA genes are 3ʹUL genes (S. Fig 1A) . In each of 106 TCGA breast tumor-matched normal sample pairs, average 56.4% of significant APA genes are 3ʹUL genes (S. Fig. 1B) . As in the case of 3ʹUS, considering significant 3ʹUL genes enables to identify much more recurring 3ʹUL genes than considering only strong 3ʹUL genes. In our TCGA breast cancer data, 83.7% of the total significant 3ʹUL genes (6,081 of 7,265) are strong (∆PDUI > 0.2) in some other samples and 3.5fold more 3ʹUL genes recur in 20% of the sample pairs when all significant 3ʹUL genes are considered (993 significant vs. 288 strong only, S. Fig. 1C ). Based on the results, investigating the common trans mechanisms of APA requires to consider all significant APA genes of both 3ʹUL and 3ʹUS.
Probabilistic Inference of MicroRNA Target Site Modification through APA (PRIMATA-
APA)
To investigate the common trans mechanisms of APA that modifies miRNA target sites, we quantify target site modifications due to significant APA events for each miRNA by developing a mathematical model, Probabilistic Inference of MicroRNA Target Site Modification through APA (PRIMATA-APA). Previously, we successfully predicted gene expression changes based on the estimated number of miRNA target sites in the presence of 3ʹUS ( _ ( , ),
Eq. 2)[8].
By extending this estimation, PRIMATA-APA estimates the total number of target sites for each miRNA with and without consideration of APA events, 3ʹUS and 3ʹUL together.
Based on the difference of the estimations, PRIMATA-APA evaluates the statistical significance of the APA-derived modification for each miRNA with the direction of the modification, either increase or decrease (see Methods). Since miRNAs play roles mainly by binding to the target sites of genes [19] , considering miRNA target site information should help us to understand their effect on transcriptomic dynamics beyond miRNA expression information.
Global miRNA target site modification due to alternative polyadenylation
To identify miRNAs affected by APA-derived target site modification, we ran PRIMATA-APA on the 70 breast tumor-matched normal samples out of 106 pairs for which miRNA expression information was available. In the data, we considered 588 moderately expressed miRNAs (> 1 and < 100 FPM on average) on the expressed genes (avg. FPKM > 1) in each sample pairs. In 39 (55.7%) of the 70 breast tumor samples, PRIMATA-APA identifies significant target site modifications (FDR < 0.01) for more than 100 miRNAs ( Fig. 2A, B) . Further, in each sample pair, miRNA target sites are either mostly increased or decreased, which makes a negative correlation between the number of target sites increased and decreased across tumor-normal sample pairs (P=0.006, Fig. 2C ).
Additionally, we found that APA events modify miRNA target sites in a subtype-specific manner. The five subtypes of breast cancer by PAM50 are known to involve distinct molecular pathways with different clinical outcomes [20] . In our TCGA breast cancer data, none of basal do not show such a bias (S. Fig. 2 ). Since both basal and Her2 subtypes are close in terms of molecular pathways and worse prognosis (reviewed in [21] , [22] ), their common pattern in miRNA target site modification suggests a similar APA landscapes between them. Altogether, the results show that APA globally modifies miRNA target sites for breast cancer in a nonrandom and a subtype-specific manner.
APA modifies target sites of miRNAs associated with cancer
To perform subsequent analyses with the focus on particular miRNAs, we identified miRNAs whose target sites are more likely modified by APA events. Based on the number of tumor samples where the target sites are significantly increased or decreased, we selected top half (289) of 588 moderately expressed miRNAs, whose target sites are more often modified than the other (299) miRNAs, which will be termed target site modified miRNA (tamoMiRNA). APA events modify target sites of tamoMiRNAs significantly more than the other miRNAs (P-value=1.12e -and biological implications [23] , regulating diverse mechanisms for breast cancer [24] , regulatory elements in either adaptive or innate immune system [25] , or potential prognostic and predictive biomarkers identified for breast cancer [26] (Fig. 3B , S. Table 1 ). Among 43 tamoMiRNAs found in the categories, 31 (72.1%) occur only in one of the categories (S. Fig. 3) , confirming that the high enrichment of tamoMiRNAs to the multiple categories reflects their important roles in tumor, not redundancy in data curation. Also, we estimated conservation score (PhyloP [27] , 46
way Placental) of 202 tamoMiRNAs and 191 other miRNAs for which miRBase [28] uniquely curated the genomic locations. TamoMiRNAs have significantly (P= 7.19e -5 ) larger conservation scores than the other miRNAs ( Fig. 3C) , implicating their functional significance. Altogether, these results indicate that, by selection or design, APA modifies target sites of miRNAs that are evolutionary conserved and functionally important for cancer etiology and treatments.
APA promotes tumorigenesis by modifying target sites of miRNAs regulating cancer
To gain insights into the cause-and-effect relationship between tamoMiRNAs and tumor growth, we revisited a previous study [29] , in which NUDT21 knockdown (KD) induced broad 3'UTRshortening, leading to enhanced cellular proliferation in HeLa cells and glioblastoma tumor growth in vitro and in vivo. Our analyses on NUDT21 experiment data (available in GEO under GSE42420 and GSE78198) validated our observations above. First, both significant-but-notstrong and 3'UL genes need to be considered for a comprehensive understanding of APA's function. Since NUDT21 is a master regulator for 3'UTR-shortening, knocking down NUDT21 yields much more strong 3'US genes (2,550 genes with ∆PDUI < -0.2 and FDR < 0.05) than 3'UL genes (84 with ∆PDUI > 0.2 and FDR < 0.05) in HeLa cells (Fig. 4A) . However, this experiment also yielded many significant-but-not-strong APA genes (615 3'UL vs. 2,847 3'US) that modifies miRNA target site landscape, where a substantial ratio (17.7%) are 3'UL genes.
Second, miRNA target site modification due to APA genes is a robust estimator for the trans effect of APA genes. To show this, we performed the following analysis on each of 383 miRNAs whose expression was available in the experiment data [8] . Given two replicate data of wild type HeLa cells (WT) and NUDT21 KD, we paired a WT and a NUDT21 KD data to make two pairs.
Then, we ran PRIMATA-APA for each miRNA to see whether the target sites increase or decrease in each pair (NUDT21 KD vs. WT). Between the pairs, we validated that the PRIMATA-APA analysis results agree across the miRNAs using Cohen's κ (P < 10e -16 ) with 97.4% of agreement (using R package 'irr'). For further analyses, we identified tamoMiRNAs for NUDT21 KD experiment as follows. With the high agreement of PRIMATA-APA calls between the sample pairs, we ran PRIMATA-APA on the averaged expression data for two WTs and two NUDT21 KD cells (S. Table 2 ). Then, we ranked the miRNAs based on the χ 2 value that indicates the degree of APA-derived target site modification (see Methods). Then, as before, the top half of the miRNAs (191) are tamoMiRNAs for NUDT21 KD experiment. It is interesting that miR-3187-3p that was extensively validated to repress tumor suppressor genes for tumorigenesis in the NUDT21 KD experiment is a tamoMiRNA [8] . We found that this experiment shares not only a significant number of strong and significant 3'US genes (91, P=9.3×10 -21 , Fig. 4B ), but also a significant number of tamoMiRNAs (119, P=1.16×10 -11 , Fig.   4C ) with the TCGA breast cancer analysis. Since both the TCGA data (tumor vs. normal) and
NUDT21 KD data represent a tumorigenic process based on 3'US, these overlaps indicate that 3'US genes and miRNA target sites they modify contribute to the tumorigenic process.
Furthermore, as the case of TCGA breast cancer data, tamoMiRNAs for NUDT21 KD are highly enriched for miRNA sets known for cancer etiology and treatments (P=0.00014, Fig. 4D ) and evolutionary conserved (P=0.04, Fig. 4E) , confirming the functional importance of tamoMiRNAs. NUDT21 KD validated the cause-and-effect relationship from APA events to tumor growth through modifying target sites of tamoMiRNAs.
APA modifies target sites of miRNAs to effectively regulate biological processes.
To further investigate the function of the miRNA target site modification in TCGA breast cancer data, we focused on the target genes of the tamoMiRNAs (see Methods). First, we identified GO terms enriched for tamoMiRs using MiEAA [30] . Probably due to the many-to-many relationships between miRNAs and target genes [31] - [33] , inputting all tamoMiRNAs and all the other miRNAs to MiEAA web server returns mostly under-represented terms. So, we focus MiEAA analysis on 99 tamoMiRNAs (with the greatest number of samples in which modified) and 105 other miRNAs (with the least number of samples in which modified). 125 and 1 biological terms are significantly (FDR < 0.01) enriched for tamoMiRNAs and for the other miRNAs respectively (S. Table 3 ). The significant bias (P-value=5.0×10 -5 ) of the number of enriched biological terms to tamoMiRNAs suggests that APA events effectively regulate biological functions. Additionally, compared to the other miRNAs, tamoMiRNAs are exclusively enriched for pathways with keyword "growth factor", "signaling", and "circadian", ( Fig. 5A, S . Table 3 ), which are essential for tumor initiation and progression [34] .
To understand their impact in regulating gene expression, we evaluated the number of genes targeted by tamoMiRNAs. Among 3,318 expressed genes in the breast tumor data that are likely controlled by miRNAs (> 5 miRNA target sites), 3,177 genes (95.7%) have more target sites for tamoMiRNAs than for the other miRNAs (Fig. 5B) 1, S. Fig. 2) , 911 genes targeted only by tamoMiRNAs are significantly more down-regulated in tumor (P=3.9e -23 ) than the same number of genes affected by other miRNAs (Fig. 5C ), suggesting that tamoMiRNAs effectively regulate gene expressions of target genes in tumor. Altogether, the results indicate that APA modifies target sites of miRNAs that effectively regulate genes in tumor-associated pathways.
APA regulates tumor-specific progression to affect interpatient heterogeneity.
As miRNAs are known to regulate cancer interpatient heterogeneity [35] , we further studied the effect of APA-derived miRNA target site modification on cancer interpatient heterogeneity. In particular, since 3ʹ-UTR shortening regulates gene expression by modifying miRNA target sites [8] , we hypothesized that variation in the degree of APA events across tumor samples diversifies the effect of miRNAs on the target genes for tumor interpatient heterogeneity. To test this hypothesis, we compared the expression variation of tamoMiRNAs, the other miRNAs and 911 of their target genes defined above. While the expression variation across the sample pairs changes equally in tumor for both tamoMiRNAs and the other miRNAs (P=0.4, Fig. 6A ), the expression variation of genes that are targeted by tamoMiRNA is significantly higher than that of the other miRNAs (P=4.9e -15 , Fig. 6B ) in tumors. Since the degree of APA events varies significantly more (P=0.004) in tumor (S . Fig. 6B) , the high variation in tamoMiRNA target gene expression in tumor is, at least partly, attributable to the APA events modifying tamoMiRNA target sites in the genes.
An example is myocin heavy chain 11 (MYH11) disruption of which is associated tumorigenesis of various types of cancer [36] - [40] . According to our miRNA-target site information, MYH11 is predicted to have a target site for a single miRNA (miRNA-124/124ab/506). Although the expression change of MYH11 is not correlated with that of the miRNA expression (S. Fig. 5A) , it is significantly (Pearson's r=0.4, P-value=0.00014, Fig. 6C) correlated with ΔPDUI values of its ceRNA partner gene, platelet-activating factor acetylhydrolase IB subunit alpha (PAFAH1B1). The functional role of PAFAH1B1 in tumor has not been widely studied, especially in association with MYH11. Our analysis found that 3ʹ-UTR of PAFAH1B1 undergoes a significant (T-test statistic=2.65, P=0.004) shortening in tumor vs.
normal. Since the 3ʹ-UTR shortening of PAFAH1B1 in tumor (negative ΔPDUI values [6] ) is expected to repress MYH11 (Fig. 6D) , the positive correlation between MYH11 expression and ΔPDUI of PAFAH1B1 (Fig. 6C) supports the role of 3ʹUS trans effect differentiating MYH11 expression. It is worth noting that the mediating miRNA, miRNA-124/124ab/506, is a tamoMiRNA (S. Table 1 ).
Further enrichment analyses support that APA-derived, miRNA-mediated [41] , [42] transcriptomic diversity contributes to interpatient difference in tumor progression. First, 911 genes targeted only by tamoMiRNAs include significantly more oncogenes than the same number of genes targeted by other miRNAs (43 vs. 28, P-value=0.03), suggesting that a varying degree of APA diversifies the effect of miRNA target activity on the oncogenic processes across tumor samples. Second, Ingenuity Pathway Analysis showed that cancer progression and migration pathways are more enriched in tamoMiRNA target genes than the target genes of the other miRNAs (P-value < 10 -3 , Fig. 6E , S. Table 4 ). Specifically, they are implicated for breast cancer often through miRNAs, e.g. with miR-494 suppressing chemokine (C-X-C motif) receptor 4 (CXCR4) for breast cancer progression [43] , miR-200c regulating Protein kinase A subunits for cancer cell migration [44] , and miR-520b targeting Interleukin-8 for breast cancer cell migration [45] (see other examples in Fig. 6E ). Since these miRNAs (miR-494, miR-200c, and miR-520b) are tamoMiRNAs of which APA modifies target sites, our results suggest that APA diversifies miRNA target site landscape for tumor-specific progression.
Discussion
Here, we studied the post-transcriptional regulation efficiency of miRNAs in presence of APA events. As miRNAs bind and repress their target genes in the post-transcriptional level, a comprehensive understanding of miRNAs' function should be based not only on their expression levels but also on the target site landscape. However, previous computational works predicted miRNAs' function based mostly on miRNA expression changes. For example, miRNAs upregulated in tumor were considered to be oncogenic miRNAs and those down-regulated were tumor-suppressive [46] , [47] . On the other hand, we characterized miRNA target site landscape modified by APA events using a mathematical model, PRIMATA-APA. Further analyses on TCGA breast cancer data clearly demonstrated that considering miRNA target site modification brings a comprehensive understanding of miRNA function in the presence of widespread APA events in tumor.
Further, our work sheds novel insights into the development of therapeutic miRNAs. The high enrichment of tamoMiRNAs to miRNAs known to regulate cancer (Fig. 3B) suggest that APA events that are associated with tumorigenesis [8] , prognosis [6] and treatment outcomes [48] make the associations by modifying target sites of tamoMiRNAs. Based on this rationale, further inspection of tamoMiRNAs would effectively narrow down miRNA search space to identify novel therapeutic miRNAs. Further, identifying miRNAs significantly associated with interpatient heterogeneity will help regulate interpatient tumor heterogeneity, which is essential for the success of early cancer detection and the development of new effective therapies [49] , [50] . For example, since MYH11's oncogenic effect is associated with a varying degree of APA events of PAFAH1B1 through miRNA-124/124ab/506 in breast cancer, molecular agents for miRNA-124/124ab/506 may help normalize different MYH11 effect on cancer patients.
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